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Simple Summary: Sarcomas are a rare group of heterogeneous tumors. Because treatment side-
effects detract from the survival benefit of treatment, it is important to assess treatment effectiveness
in terms of patient-reported health-related quality of life (HRQoL). However, a sarcoma specific
measurement instrument or strategy does currently not exist. This study aims to (1) develop a list of
all HRQoL issues relevant to sarcoma patients; (2) determine a strategy for sarcoma-specific HRQoL
assessment. An international, multicenter study will be conducted, searching existing literature and
conducting interviews with adult sarcoma patients and healthcare professionals (HCPs) to create a
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list of HRQoL issues. Subsequently, another group of sarcoma patients and HCPs will be asked to rate
and prioritize the issues. This information will help create a strategy to measure HRQoL in sarcoma
patients, taking into account the heterogeneity of sarcomas, which will improve the collection of
personalized patient-reported outcome data in future research and clinical care.
Abstract: Sarcomas comprise 1% of adult tumors and are very heterogeneous. Long-lasting and
cumulative treatment side-effects detract from the (progression-free) survival benefit of treatment.
Therefore, it is important to assess treatment effectiveness in terms of patient-reported outcomes
(PROs), including health-related quality of life (HRQoL) as well. However, questionnaires capturing
the unique issues of sarcoma patients are currently lacking. Given the heterogeneity of the disease,
the development of such an instrument may be challenging. The study aims to (1) develop an
exhaustive list of all HRQoL issues relevant to sarcoma patients and determine content validity;
(2) determine a strategy for HRQoL measurement in sarcoma patients. We will conduct an interna-
tional, multicenter, mixed-methods study (registered at clinicaltrials.gov: NCT04071704) among bone
or soft tissue sarcoma patients ≥18 years, using EORTC Quality of Life Group questionnaire de-
velopment guidelines. First, an exhaustive list of HRQoL issues will be generated, derived from
literature and patient (n = 154) and healthcare professional (HCP) interviews (n = 30). Subsequently,
another group of sarcoma patients (n = 475) and HCPs (n = 30) will be asked to rate and prioritize
the issues. Responses will be analyzed by priority, prevalence and range of responses for each item.
The outcome will be a framework for tailored HRQoL measurement in sarcoma patients, taking into
account sociodemographic and clinical variables.
Keywords: sarcomas; soft tissue sarcoma; bone sarcoma; health-related quality of life; patient-
reported outcomes
1. Introduction
Sarcomas are a group of rare malignant solid neoplasms of mesenchymal origin, com-
prising more than 100 histological and more than 250 molecular subtypes [1]. Significant
heterogeneity exists among cases with widely different patterns of the stage at diagnosis,
tumor location at almost any anatomical site, prognosis, treatments, and age at diagno-
sis [2]. Sarcomas can be classified into soft tissue sarcomas (STS), including gastrointestinal
stromal tumors (GIST) (84% of all sarcomas) and bone sarcomas (BS; 14%), and other sarco-
mas [3]. The overall incidence of sarcoma is about 7 in 100,000 persons, with 30,000 new
cases a year in Europe [3].
Approximately 10% of patients present with de novo metastatic disease. Furthermore,
many sarcomas have aggressive biological behavior, and around half of patients with
high-grade tumors will eventually develop incurable metastatic disease [4,5]. The five-year
relative survival in Europe (period 2000–2007) is 60% for STS and 50% for BS [6]; however,
survival in the metastatic setting is poor; for example, in STS, median overall survival is
12–20 months [6,7] but may be many years in exceptional cases.
Treatment for localized STS usually consists of conservative surgery with pre- or post-
operative radiotherapy, however in retroperitoneal STS extended multivisceral resection is
often needed in order to obtain complete resection and reduce the risk of recurrence [8].
The evidence for (neo-)adjuvant chemotherapy is controversial; however, it may be consid-
ered in high-risk tumors. In patients with advanced STS, not amenable to curative surgical
resection, systemic treatment with chemotherapy is the mainstay of therapy with the aim
to relieve symptoms, slow tumor progression and prolong survival. In some sarcoma
subtypes, other systemic options are available, including tyrosine kinase inhibitors [9–11],
but access may be limited in some countries. Immunotherapy has shown some promise in
trials of some advanced STS. However, no treatment has yet been approved [12]. Surgi-
cal resection, stereotactic ablative radiotherapy or local treatments such as radiofrequency
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ablation of oligo-metastases can be considered in selected cases [13]. Generally, conven-
tional radiotherapy is applied in the palliative setting, mainly for pain reduction.
The treatment of BS also differs per subtype. In patients with localized chondrosar-
coma, surgery alone is the standard of treatment. Ewing sarcoma and osteosarcoma patients
will have surgery in addition to (neo)adjuvant chemotherapy. For Ewing sarcoma patients,
radiotherapy can be delivered either instead of surgery, in cases where surgery would be
morbid or significantly impact functional outcomes, but more often in the (neo) adjuvant
setting. For patients with advanced BS, palliative chemotherapy and/or radiotherapy are
potential therapeutic options.
Despite the effectiveness of treatments for sarcoma, the varying degrees of long-lasting
and cumulative treatment side-effects and morbidity in a substantial number of patients
contribute negatively to their overall outcome [8,14,15]. Information on survival only
is insufficient to determine the net clinical (or true) benefit of a treatment for patients,
and subjective patient-reported outcomes (PROs), including health-related quality of life
(HRQoL), should be considered as well. HRQoL is a multidimensional concept that
includes the patient’s perception of the impact of their disease and treatment on physical,
psychological, and social functioning in daily life [16]. Measurement of HRQoL facilitates
the calculation of quality-adjusted life years (QALY), defined as “the measure of the state of
health of a person or group in which the benefits, in terms of length of life, are adjusted to
reflect the quality of life” [17]. PROs are increasingly used as important endpoints in cancer
clinical trials, and implementation has become more standardized [18,19]. Furthermore,
studies have shown that using PROs in clinical practice leads to better patient-provider
communication, more symptom control and patients are more willing to self-report their
symptoms from home [20–23].
The availability of high-quality HRQoL data of sarcoma patients is limited but shows
they have more physical and psychological problems than the general population [24,25].
Patients experience disabling disease- and treatment-related symptoms such as fatigue
and pain, interference in family, social and vocational life, and limitations in leisure activ-
ities, which can, in turn, impact their mental health and confidence [14,26,27]. Existing
HRQoL data in sarcoma patients is mostly based on the use of generic (SF-36, EQ-5D)
or cancer-generic (EORTC-QLQ-C30, FACT-G) questionnaires; however, these measures
do not cover all sarcoma- or sarcoma treatment-specific problems. For example, in the
PALETTE trial (EORTC 62072), a double-blind, randomized, phase 3 trial of pazopanib
versus placebo as second-line or later treatment for patients with advanced STS, HRQoL
was an exploratory endpoint, using the EORTC QLQ-C30 [28]. Although HRQoL did not
improve with pazopanib, the observed improvement in progression-free survival without
impairment of HRQoL was considered a relevant result. The toxicity profile of pazopanib
was reflected in the patients’ self-reported symptoms (e.g., diarrhea) but did not translate
into significantly worse overall global health status during treatment. However, several
other side-effects common to angiogenesis inhibitors (e.g., hand-foot syndrome or skin reac-
tions) were not assessed as PROs in this study. Another study reported that bone sarcoma
survivors struggle with their altered appearance and display of functional impairments
(e.g., walking with a limp or needing a crutch), which impacts their self-esteem and social
life [29]. This is not covered by existing (cancer-)generic questionnaires. Thus, to fully
understand and assess in detail the impact of this sarcoma treatment on all domains of
HRQoL, in both clinical research and care, the use of HRQoL measure(s) that includes
sarcoma-specific treatment symptoms or issues is needed.
Usually, the development of a tumor-specific module resolves the problem of insuffi-
cient content coverage of a generic measure. A comprehensive sarcoma-specific HRQoL
measure for use in clinical trials is currently lacking, as existing HRQoL measures for
sarcoma patients are focused on physical functioning only (e.g., Toronto extremity salvage
score (TESS) as a measure of physical disability [30]) or patient experiences (e.g., sarcoma as-
sessment measure (SAM) [31]). However, it was found during the development process of
the SAM that tumor location and type of treatment received are important factors that de-
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termine which HRQoL issues subgroups of sarcoma patients are dealing with, in addition
to established factors including sex and age [32,33]. For example, five issues (not specified)
were identified to be only relevant in patients who had undergone amputation, and nine
issues were relevant to head and neck sarcoma patients [31]. This heterogeneity of the dis-
ease was also reflected in HRQoL outcomes in German sarcoma patients and survivors [34].
These data show that the development of a single instrument is challenging, and it may
not be the best option to meet the needs of academia and industry to assess the impact of
new treatments [15,35].
The European Organization for Research and Treatment of Cancer Quality of Life
Group (EORTC QLG) is currently developing a new measurement strategy, shifting to a
more flexible approach that allows for the use of customized measures, in addition to the
“static” standardized questionnaires, where relevant [36]. Traditionally, questionnaires are
developed during a 4-phase process which takes several years, i.e., (1) generation of HRQoL
issues, (2) construction of an item list, (3) pretesting the provisional questions, (4) field-
testing to determine reliability, validity and responsiveness [37]. The new approach entails
the use of a combination of standardized HRQoL questionnaires (i.e., the EORTC Quality
of Life Questionnaire Core 30 (EORTC QLQ-C30) and existing disease-, site, or population-
specific modules to enable population comparison, and validated items from the so-called
Item Library (an online platform comprised of more than 900 individual items from
over 60 EORTC questionnaires) to cover the full range of issues relevant for the study
population (depending on the research question) [38]. Item banks also enable computer
adaptive testing (CAT) techniques, tailoring the selection of items based on responses to
previous items [39,40]. This flexible approach offers the possibility to encompass the full
range of age-, location- and treatment-specific issues relevant to sarcoma patients and to
improve the relevance for patients in answering questions that are meaningful to them.
Furthermore, it also allows for shorter questionnaires, which makes compliance to a repeat
routine more likely and opens the way to longitudinal measurement, which patients find
improves understanding [41].
This study aims to develop an exhaustive list of all HRQoL issues relevant to sarcoma
patients (irrespective of their sarcoma stage, subtype, treatment, age) and to determine
content validity. Subsequently, a strategy for HRQoL measurement in sarcoma patients
will be determined that will allow for tailored, longitudinal assessment based on sociode-
mographic and clinical variables in future clinical trials.
2. Methods and Analysis
2.1. Study Design and Setting
We will conduct a cross-sectional, international, multicenter, mixed-method phase 1
questionnaire development study among bone and soft tissue sarcoma patients at more
than thirty centers world-wide, following EORTC QLG questionnaire development guide-
lines [37]. First, a list of HRQOL issues will be generated, derived from the available
literature and patient- and healthcare professional (HCP) interviews. Subsequently, an-
other group of sarcoma patients and HCPs will be asked to rate the issues on relevance
and to prioritize the most important issues. Clinical data will be extracted from patient
records. The study started already with recruitment at the first center in May 2019, and a
systematic review of the literature has recently been published [42].
2.2. Patient and Public Involvement
Implementation of HRQoL and other PRO assessments in sarcoma research is one of
the research priorities of the Sarcoma Patients EuroNet (SPAEN), an international network
of sarcoma, GIST, and Desmoid patient advocacy groups. Furthermore, public involve-
ment is an integral aspect of patient-reported outcome measure (PROM) development [43].
Patient representatives were involved in the design of the study (feedback on the protocol
and patient information form) and will be involved in reporting the results. In several coun-
tries, local patient advocacy groups will disseminate information about this study among
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their members to increase awareness about this project and to encourage participation.
Study results will also be shared with patients through these organizations.
2.3. Eligibility Criteria
Inclusion criteria are: (1) confirmed diagnosis of sarcoma (according to the ICD-10
codes C40 and C41 for bone sarcoma and C49 for soft-tissue sarcoma). Patients with
all stages of the disease, and both during treatment or posttreatment follow-up, will be
included. The primary types of treatment to be included are surgery, radiotherapy, sys-
temic treatment, or a combination; (2) age ≥ 18 years. Although sarcoma is a disease
affecting all ages and sarcoma patients aged < 18 years are seen within adult health services
in some countries, only those aged 18 years and older will be included because the EORTC
QLQ-C30 is only validated among cancer patients aged 18 years and older. The EORTC
Quality of Life Group is currently conducting a study to identify unique HRQoL issues
specific to adolescents and young adults (AYAs; aged 14–39 years) with cancer and to
validate the EORTC QLQ-C30 in young people with cancer [44]. Depending on the results
of this study, a measurement strategy for AYA sarcoma patients can be determined at a
later stage (3) having the mental capacity to provide informed consent and participate
in the study (as determined by their treating physician). Patients must be able to rate
or complete questionnaires themselves, as a prerequisite for patient-reported outcome
measures; (4) medical professionals, e.g., surgical oncologist, medical oncologist, radiation
oncologist or clinical oncologist, nurse, social worker, psychologist, a physiotherapist with
experience of working with sarcoma patients.
Exclusion criteria are: (1) being too ill (on the judgment of the treating physician);
the following diagnoses: (2) GIST; (3) Kaposi sarcoma; (4) carcinosarcoma; (5) benign and
locally aggressive mesenchymal tumors.
2.4. Data Collection
2.4.1. Literature Review
First, a search of the literature through four medical search engines has been performed
to identify all relevant HRQoL issues and existing HRQoL questionnaires currently used
among sarcoma patients. The search strategy was created with the help of a librarian and
combined medical subject headings (MeSH) terms and keywords for sarcoma and quality
of life [42]. The reference lists of all identified publications will be reviewed to retrieve other
relevant publications. There will be no restrictions with regard to the year of publication.
This literature search will result in a list of HRQoL issues relevant to sarcoma patients,
which will be used to develop the issue list.
2.4.2. Part A: Interviews
First, the respondent will be asked an open question about his/her sarcoma history
and experience and then be prompted according to the interview schedules (one for patients
and one for HCPs) that will be provided for all collaborators to ensure homogeneity in data
collection (Supplementary Material, text S1). Subsequently, the respondent will be asked to
review the EORTC QLQ-C30 and a site-specific module, if available, for the topic and item
relevance (to be scored on a 4-point Likert scale of relevance for the survivorship period).
Those with a sarcoma in the head and neck region will be asked to complete the EORTC
QLQ-H&N43 and those with a uterine sarcoma the EORTC QLQ-EN24 to determine the
relevance of these existing site-specific items of these questionnaires in sarcoma patients.
All patients will receive a copy in their own language. The respondent will be encouraged
to “think aloud”, providing feedback on the reasons for his/her ratings. The respondents
will also be asked to identify HRQoL issues that they believe to be important that are not
included in the current core questionnaire and, where relevant, site-specific module.
This list of HRQoL issues generated by the literature search and semi-structured
patient and HCP interviews will be consolidated into a comprehensive list of issues for all
languages of collaborating countries.
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2.4.3. Part B: Review Issue-List
The new list of HRQoL issues will be administered to another group of sarcoma
patients and HCPs. Patients and HCPs will be asked to rate the HRQoL issues on relevance
(4-point Likert scale: (1) not relevant–(4) very relevant), to prioritize the 25 most important
issues, and to indicate relevant issues missing from this list. Patients will also be asked to
complete the EORTC QLQ-C30. In addition, those with a sarcoma in the head and neck
region are asked to complete the EORTC QLQ-HN43 and those with a uterine sarcoma the
EORTC QLQ-EN24.
2.5. Recruitment
Patients will be recruited from Northern Europe (e.g., Germany, The Netherlands,
Norway), Central/Eastern Europe (e.g., Poland), Southern Europe (e.g., Cyprus, France,
Italy, Spain), the United Kingdom and also in countries outside Europe, including Australia,
Canada, Hong Kong, India, Israel, Jordan, and the United States.
The study coordinator will use stratification to ensure that subjects represent the target
population and will communicate to the local collaborators which patients can be invited.
Purposive sampling will aim to achieve good representation according to sex, age, sarcoma
location and treatment. When selecting the patients for interviews, care will be taken
to include both younger and older patients, males and females, all types of treatment,
as well as newly diagnosed patients and patients in posttreatment follow-up. We will
stratify our sample according to the 6 locations of sarcoma (upper and lower extremities,
axial skeleton, retroperitoneal/intra-abdominal, head and neck including the scalp, tho-
rax including breast, and pelvic organs including urogenital), disease stage (localized,
metastatic disease/local relapse) and subtype (bone sarcoma, soft tissue sarcoma) to ensure
the heterogeneity of sarcomas in terms of subtypes, treatments, age, sex, and physical
impairments is adequately covered (Table 1). These characteristics are based on the clinical
experience of health care professionals and researchers in the sarcoma field and input from
patient representatives.
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a Covered by axial group; SU = surgery; ST = systemic therapy (e.g., chemotherapy, tyrosine kinase inhibitors, immunotherapy); RT =
radiotherapy; BSC = best supportive care; local treatment = SU and/or RT in metastatic setting.
During part A, eligible patients will be identified from the Medical Oncology, Radia-
tion Oncology or Surgery departments of the participating hospitals and through patient
organizations. The health care professional will introduce the study to eligible patients. If a
patient expresses interest, he or she will be approached by the researcher for further details
about the study, the interview, and the agreement to participate.
In part B, patients will be selected by the clinical team in the participating hospitals
and invited to participate in the study using an invitation letter signed by the treating
physician or in person during a routine follow-up appointment. Within one week, they will
be contacted by phone to explain the study and to ask if they are willing to participate. If
they are willing to participate, they will receive by mail an informed consent form, the issue
list and the EORTC QLQ-C30 questionnaire (and EORTC QLQ-H&N43 or -EN24 module if
applicable).
During both part A and part B, HCPs with experience of working with sarcoma
patients will be invited by the study coordinator or the local PI.
2.6. Case Report Forms
Sociodemographic data will be collected at study entry, including age, gender, level of
education and employment status, living arrangements, travel distance to hospital, and ac-
cess to centralized care. These data may be extracted from the dossier or obtained from the
patient directly. Clinical data will also be collected, including primary diagnosis, stage of
the disease, type of therapy (if any), and comorbidity using the Charlson comorbidity index
and international prognostic index (IPI) [45]. These clinical data will be extracted from the
medical file and noted on the demographic and clinical data form. The information will
be recorded and stored in accordance with the Dutch General Data Protection Regulation.
Data linkage will be done at the Netherlands Cancer Institute.
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2.7. Questionnaires
Three existing EORTC quality of life questionnaires will be reviewed by patients and
HCPs, for the topic and item relevance. The EORTC QLQ-C30 is provided for all patients,
the EORTC QLQ-H&N43 for patients with sarcoma in the head and neck region and the
EORTC QLQ-EN24 for patients with uterine sarcoma. Before the start of phase 1b, based
on the issues found in phase 1a, it will be evaluated if more location-specific modules (e.g.,
prostate, breast or colorectal) can be included. All scales and single-item measures range
from 0 to 100 after linear transformation. A higher score on functional scales and global
QoL means better functioning and HRQoL, whereas a higher score on the symptom scales
means more complaints.
2.7.1. EORTC-Quality of Life Questionnaire (EORTC QLQ-C30)
The EORTC QLQ-C30 version 3.0 was developed to measure HRQoL in patients with
cancer [46]. It was translated into and linguistically validated into over 110 languages.
This 30-item questionnaire consists of five functional scales (physical, role, cognitive,
emotional and social), a global health status/quality of life scale, three symptom scales
(fatigue, pain, nausea and vomiting) and six single items assessing common symptoms
(dyspnea, loss of appetite, insomnia, constipation and diarrhea) and perceived financial
impact of the disease.
2.7.2. EORTC-QLQ-Head and Neck Module (EORTC QLQ-H&N43)
The EORTC QLQ-Head and Neck Module (EORTC QLQ-H&N43) measures HRQoL
in patients with head and neck cancer [47]. It has been translated into and linguistically
validated in 29 languages. It consists of 43 items, divided into 12 symptom scales (pain in
the mouth, swallowing, problems with teeth, dry mouth and sticky saliva, problems with
senses, speech, body image, social eating, sexuality, problems with shoulder, skin problems
and fear of progression) and 7 single items (problems opening the mouth, coughing, social
contact, swelling in the neck, weight loss, problems with wound healing and neurological
problems).
2.7.3. EORTC-QLQ-Endometrial Cancer Module (EORTC QLQ-EN24)
The EORTC QLQ-Endometrial Cancer Module (EORTC QLQ-EN24) was developed
for HRQoL measurement in patients with endometrial cancer and consists of 24 items [48].
It has been translated into and linguistically validated in 35 languages. Five symptom
scales (lymphedema, urological symptoms, gastrointestinal symptoms, poor body image
and sexual/vaginal problems), five single symptoms items (pain in back and pelvis, tin-
gling/numbness, muscular pain, hair loss and taste change) and three single functional
items (sexual interest, sexual activity and sexual enjoyment) are measured.
2.8. Objectives
The primary objective is to develop an HRQoL measurement strategy for sarcoma
patients, indicating which issues can be included for all sarcoma patients (sarcoma-generic)
and which issues should be evaluated in certain subgroups (e.g., based on treatment or
sarcoma location) only. This is the first step towards the implementation of sarcoma specific
PROs in future clinical trials. Secondary endpoints are: (1)to develop an exhaustive list
of all HRQoL issues relevant to sarcoma patients (irrespective of their sarcoma subtype,
treatment, time since diagnosis and age, and including generic/specific issues), (2) to
determine the proportion of patients in each subgroup (according to tumor localization,
type of sarcoma, disease stage and treatment) rating each item and the items from the
EORTC QLQ C30 as relevant (i.e., rating 2–4 on Likert scale indicates relevance), (3) to
determine the proportion of respondents with head neck or uterine localization rating
each site-specific item of the H&N43 or EN24 questionnaire as relevant (i.e., rating 2–4 on
Likert scale indicates relevance), (4) to determine the proportion of subgroups rating each
item as relevant (i.e., half subgroups rating an item as relevant indicates a sarcoma-generic
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issue), and (5) to determine subgroup-specific (according to localization, type of treatment,
subtype and disease stage) issues using a comparative approach (issues cited at least 1.5
times more indicates subgroup-specificity).
2.9. Sample Size Calculation
Part A: No formal sample size calculation can be made for the interviews. Data
collection continues until saturation is reached, which is usually after 12 patients in phe-
nomenological research [49]. Saturation occurs when adding more participants to the
study (or, in this case, subgroup) does not result in additional perspectives or information.
A stratification matrix (Table 1) will be used that ensures that at least 12 patients per location
and 10 per treatment will be interviewed, considering the incidence of sarcoma location
and treatment. In total, 154 patients will be recruited. Although some locations will be
overrepresented in this sample compared to the population-based incidence numbers,
this proportion was chosen to make sure that enough patients are enrolled per group to be
able to conduct subgroup analyses.
Part B: Although the EORTC guidelines for development state that no more than
10 patients should be included in this part, the heterogeneity of the sarcoma population
requires greater numbers for adequate subanalyses. Again, at least 10 patients per location
and 10 per treatment will be recruited (Table 1), leading to a total of 475 patients.
Healthcare professionals: According to the EORTC module development guidelines,
at least 5 HCPs should be included; therefore, 5 HCPs will be interviewed for each location
(i.e., 6 in total), which means 30 HCPs in total. This applies to both parts A and B.
2.10. Statistical Analysis
We will perform thematic analysis of the qualitative data. Transcripts of the patient
and HCP interviews will be examined by two coders in detail in order to identify basic
patterns and recurrent themes using line-by-line coding to examine, compare and begin to
develop conceptual categories. Categories will be developed inductively using the constant
comparison method. Comparing each item with the rest of the data to create analytical
categories, and then grouping categories together will make it possible to identify key
themes [50]. The consolidated criteria for reporting qualitative research (COREQ) will be
followed to ensure the accuracy of this qualitative study [51].
Data from patient and HCP interviews and questionnaires will be analyzed according
to the EORTC module development guidelines [36], using basic quantitative analyses,
including descriptive statistics (e.g., missing data, means and standard deviations, floor
and ceiling effects), prevalence (number of patients who experienced each complaint, i.e.,
who scored 2, 3 or 4, divided by the total number of patients who completed that item,
multiplied by 100), priority ratings (number of patients and professionals who have given
priority ratings to each item) and range of responses for each item.
In order to facilitate transparent decision-making concerning the best approach to
take in developing a sarcoma measurement strategy, the existing decision criteria will be
followed: (1) an inclusive approach will be taken with regard to relevant items; (2) inclusion
of an issue will be considered when more than 30% of patients (in total or per subgroup)
mention the issue as missing; (3) issues that have a low (e.g., mean <1.5) mean score for
relevance or importance will be considered for exclusion.
To distinguish “sarcoma generic” from “subgroup-specific issues”, issues that are
more or less frequent in specific subgroups will be evaluated. An issue will be coded as
endorsed by a respondent if it was scored 2 (“a little relevant”) or higher on the 4-point
response scale. An issue needs to be endorsed by at least 30% of the patients in a subgroup
to be included as an issue in that subgroup. If an issue is endorsed by patients from 3 out
of 6 tumor locations and 2 out of 4 treatment groups, it will be considered to be a generic
sarcoma issue; otherwise, it can be considered a sarcoma subgroup-specific issue.
Additional analyses will be performed per subgroup for location, treatment(s) received
(surgery; chemotherapy/targeted therapy; radiotherapy; no treatment), type of sarcoma
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(soft tissue vs. bone sarcoma), and disease stage (localized vs. metastatic). An issue needs
to be endorsed by at least 30% of the patients in a subgroup, and the mean score needs to
be 1.5 or higher to be included as an issue in a subgroup. Then the prevalence of each issue
between the aforementioned subgroups (according to location, type of treatment, subtype
and disease stage and combinations of these factors) will be compared to decide whether
an issue is subgroup-specific. Issues that are cited by at least 1.5 times as many respondents
in group A compared to group B (a ratio of 3:2) may be considered as subgroup-specific.
For head and neck, and uterine sarcoma patients, the scores on the H&N43 and EN24
will be analyzed. We will assess the prevalence (percentage of the subjects who score higher
than 2 is >30% and a mean score of 1.5 or higher) of each site-specific item. When at least
80% of the items are prevalent, using the site-specific module for those sarcoma locations
will be recommended.
All the collected information will help to advise researchers as to which factors need to
be taken into account when creating an item list for a specific study focusing on subgroups
of sarcoma patients.
2.11. Missing Data
We will describe the number of missing items (i.e., number of items or questions that
were not rated for relevance by patients or HCPs) and describe these results in our findings.
3. Conclusions
Sarcoma diagnosis and treatment have a substantial impact on a patient’s HRQoL,
which should be taken into account in research and organization of care for this patient
group. This study will be the first to investigate the optimal strategy for the assessment
of HRQoL in sarcoma patients. Measurement of HRQoL in the sarcoma population is
challenging because of heterogeneity in terms of locations, subtypes, treatments, age,
and prognosis, and a holistic measurement strategy or instrument does currently not
exist. The multicenter, international design of the study enables adequate sample sizes for
specific subgroups of this rare cancer and ensures a multi-ethnic background of participants.
Furthermore, the use of purposive sampling allows for coverage of the previously described
heterogeneity of sarcomas. Our results will help to ensure the collection of high-quality,
personalized patient-reported outcome data in future clinical trials and observational
studies, eventually improving tailored supportive care for sarcoma patients.
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